Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.
Oudard S, Joly F, Geoffrois L, Laguerre B, Houede N, Barthelemy P, Gross-Goupil M, Vano Y, Lucidarme O, Bidault F, Kelkouli N, Slimane K, Escudier B. Oudard S, et al. Among authors: slimane k. Clin Genitourin Cancer. 2016 Dec;14(6):e595-e607. doi: 10.1016/j.clgc.2016.04.019. Epub 2016 May 2. Clin Genitourin Cancer. 2016. PMID: 27283478
A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France.
Joly F, Eymard JC, Albiges L, Nguyen T, Guillot A, Rolland F, Spaeth D, Laguerre B, Lebret T, Kelkouli N, Slimane K, Ravaud A. Joly F, et al. Among authors: slimane k. Support Care Cancer. 2017 Jul;25(7):2055-2062. doi: 10.1007/s00520-017-3594-y. Epub 2017 Feb 10. Support Care Cancer. 2017. PMID: 28188447
Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
Thiery-Vuillemin A, Theodore C, Jacobasch L, Schmitz J, Papandreou C, Guillot A, Emmanouilides C, Slimane K, Kelkouli N, Kim S, Nguyen Tan Hon T. Thiery-Vuillemin A, et al. Among authors: slimane k. Clin Genitourin Cancer. 2015 Jun;13(3):231-8. doi: 10.1016/j.clgc.2014.09.005. Epub 2014 Nov 20. Clin Genitourin Cancer. 2015. PMID: 25456838
Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
Erman M, Biswas B, Danchaivijitr P, Chen L, Wong YF, Hashem T, Lim CS, Karabulut B, Chung HJ, Chikatapu C, Ingles S, Slimane K, Kanesvaran R. Erman M, et al. Among authors: slimane k. BMC Cancer. 2021 Sep 14;21(1):1021. doi: 10.1186/s12885-021-08738-z. BMC Cancer. 2021. PMID: 34521387 Free PMC article. Clinical Trial.
Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy.
de Crevoisier R, Slimane K, Messai T, Wibault P, Eschwege F, Bossi A, Koscielny S, Bridier A, Massard C, Fizazi K. de Crevoisier R, et al. Among authors: slimane k. Ann Oncol. 2010 Apr;21(4):808-814. doi: 10.1093/annonc/mdp365. Epub 2009 Oct 13. Ann Oncol. 2010. PMID: 19825885 Free article.
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
Im YH, Karabulut B, Lee KS, Park BW, Adhav A, Cinkir HY, Abdel-Razeq H, Chang YC, Aksoy S, Im SA, Jeong J, Chae Y, Bowles J, Slimane K, Xue H, Kim SB. Im YH, et al. Among authors: slimane k. Breast Cancer Res Treat. 2021 Jul;188(1):77-89. doi: 10.1007/s10549-021-06173-z. Epub 2021 Mar 16. Breast Cancer Res Treat. 2021. PMID: 33728524
28 results